WORKING GROUP NAME: CTD-ILD

Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and
idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality. Great efforts are under way
to develop and investigate meaningful treatments in the context of clinical trials. However, efforts
have been challenged by a lack of validated outcome measures and by inconsistent use of measures
in clinical trials.